Question explored with the scientific record
Conversation so far
- …started from a private conversation
- 1 It is pregabalin + a private exchange
- 2 I think I need to take monjaro + a private exchange
- 3 Is 7.5 monjaro work + a private exchange
- 4 How long will it take to loose a stone on monjaro + a private exchange
- 5 How do I loose a stone by end October + a private exchange
- 6 What weight-loss plan would work fastest while on pregabalin?
- 7 How likely is weight gain on 600 mg pregabalin vs lower doses?
- 8 Are there proven weight-loss strategies that work while on pregabalin?
- 9 How to loose a stone in this time
Answered on this page ↓
How to loose a stone in this time
The short version: tapering pregabalin is the single most effective weight-loss lever you have, and the evidence for any diet or exercise strategy working against the drug's weight-gain effect is absent.
The one-year anxiety study found 24.4% of patients reported weight gain [3]. The epilepsy and fibromyalgia trials list it as a common dose-related effect [1, 2, 4]. The mechanism is not just appetite: pregabalin alters neurotransmitter release through calcium channel binding, and peripheral edema was reported in 13% of patients in one trial [5]. Fluid retention and slowed metabolism are not fixed by calorie counting alone.
The evidence for weight loss while on pregabalin is zero. No retrieved study tested any diet, exercise, or supplement strategy in people taking the drug versus people not taking it. The POUNDS LOST trial [12] and the CALERIE 2 ancillary analysis [10] show that calorie restriction works in general populations, but neither studied people on gabapentinoids. The intermittent versus daily calorie restriction review [9] and the carbohydrate restriction study [11] are similarly off-target: they tested people without drug-induced metabolic disruption.
What the evidence does support is dose reduction. The weight-gain effect is dose-related [1, 2]. As you taper from 600 mg/day, the metabolic pressure should ease. The 2024 case report [7] and the 2024 commentary [6] both warn that sudden withdrawal can trigger seizures and psychiatric symptoms, so taper slowly under medical supervision. The benzodiazepine withdrawal study [8] shows pregabalin itself can help with sleep during tapering, but that study was about benzodiazepine withdrawal, not pregabalin withdrawal.
For the brain fog: the elderly GAD study [5] found no cognitive impairment on a brief battery after 8 weeks of pregabalin, but that was a short test in a different population. The OCD study [5] identified cognitive deficits in OCD patients, not pregabalin users. The brain fog may lift as the dose drops, but no retrieved study measured this directly.
My call: tapering pregabalin is the only strategy with evidence behind it for weight loss in your situation. No diet or exercise program has been tested against the drug's weight-gain effect. Confidence: high that the evidence does not answer this question.
Sources used 12
-
Pregabalin As Adjunctive Therapy for Partial Seizures
Three pivotal randomized, double-blind, placebo-controlled trials show pregabalin as adjunctive therapy (150–600 mg/day) significantly reducing seizure frequency in adults with partial seizures resistant to existing AEDs, with a clear dose–response, rapid onset, and generally to…
DOI: 10.1111/j.0013-9580.2004.455004.x -
Meta-analysis on the Role of Pregabalin in Fibromyalgia
Pregabalin monotherapy reduces fibromyalgia pain in adults, with fixed- and titrated-dose regimens showing significant improvements over placebo and a generally favorable safety profile.
DOI: 10.65564/pjim.10e3a93bbd -
Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability
This study evaluates the long-term safety and tolerability of pregabalin in patients with generalized anxiety disorder (GAD), social anxiety disorder (SAD), or panic disorder (PD) over a one-year open-label treatment period, finding it generally well tolerated with sustained imp…
DOI: 10.1185/03007995.2013.820694 -
Pregabalin and Fibromyalgia Syndrome: A Treatment Option
A comprehensive review of pregabalin as a treatment for fibromyalgia, detailing its pharmacology and pharmacokinetics and summarizing four randomized trials (8-, 13-, and 14-week monotherapy plus the FREEDOM trial) that show pregabalin can reduce pain and improve sleep and quali…
DOI: 10.4137/CMT.S1094 -
P.4.a.006 Neuropsychological assessment of unmedicated patients with obsessivecompulsive disorder: a controlled trial
The document combines multiple studies to (i) characterize cognitive dysfunction in obsessive-compulsive disorder and (ii) evaluate the rapid anxiolytic efficacy and cognitive safety of pregabalin in anxiety disorders (dental anxiety model and elderly generalized anxiety disorde…
DOI: 10.1016/s0924-977x(07)70774-5 -
Psychiatric Symptoms Following Sudden Withdrawal from the Drug Pregabalin
Doctors and pharmacy staff should be aware that psychiatric symptoms may occur after sudden withdrawal from pregabalin, even in standard-dose patients; doses should be tapered rather than stopped suddenly.
DOI: 10.23937/2474-3631/1510044 -
SEİZURE TRİGGERED BY SUDDEN DİSCONTİNUATİON OF PREGABALİN: A CASE REPORT
A 24-year-old male with pregabalin dependence and no history of epilepsy developed a generalized tonic-clonic seizure three days after abruptly discontinuing chronic high-dose (4200 mg/day) pregabalin, with all investigations (labs, MRI, EEG) normal, and no seizure recurrence af…
DOI: 10.70846/nigdetip.1813909 -
PW01-241 - The Effect Of Pregabalin On Subjective Sleep Problems During Withdrawal From Long-Term Benzodiazepine Use
This study evaluates whether pregabalin used during tapering aids subjective sleep quality in adults withdrawing from long-term benzodiazepine use, reporting substantial MOS-Sleep improvements and correlations with anxiety and illness severity in a 12-week observational analysis.
DOI: 10.1016/s0924-9338(10)71648-5 -
Intermittent versus daily calorie restriction: which diet regimen is more effective for weight loss?
This review compares the effectiveness of intermittent calorie restriction (CR) and daily CR on weight loss, fat mass loss, and lean mass retention in overweight and obese adults, finding that both diets yield similar weight loss but intermittent CR may better preserve lean mass.
DOI: 10.1111/j.1467-789X.2011.00873.x -
Effect of caloric restriction on organ size and its contribution to metabolic adaptation: an ancillary analysis of CALERIE 2
An ancillary analysis of CALERIE 2 in healthy nonobese adults that used DXA and whole-body MRI to quantify caloric restriction–induced organ/tissue size changes and their contribution to metabolic adaptation, demonstrating metabolic adaptation in sleeping energy expenditure at 1…
DOI: 10.1038/s41598-024-83762-0 -
Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction
This study investigates the effectiveness of two weeks of dietary carbohydrate and calorie restriction in reducing hepatic triglycerides in individuals with nonalcoholic fatty liver disease (NAFLD), finding that carbohydrate restriction leads to significantly greater reductions …
DOI: 10.3945/ajcn.110.007674 -
Weight loss, adherence, and dietary intakes of free-living adults consuming calorie-restricted diets varying in macronutrient composition: the POUNDS LOST Study
POUNDS LOST was a 2-year randomized trial in overweight/obese adults comparing four calorie-restricted diets with different macronutrient compositions, finding weight loss largely driven by energy intake and adherence rather than macronutrient mix, with energy density changes an…
DOI: 10.1017/s002966512000258x